GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Protagenic Therapeutics Inc (NAS:PTIX) » Definitions » PB Ratio

Protagenic Therapeutics (Protagenic Therapeutics) PB Ratio : 1.70 (As of Apr. 30, 2024)


View and export this data going back to 2003. Start your Free Trial

What is Protagenic Therapeutics PB Ratio?

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2024-04-30), Protagenic Therapeutics's share price is $1.41. Protagenic Therapeutics's Book Value per Share for the quarter that ended in Dec. 2023 was $0.83. Hence, Protagenic Therapeutics's PB Ratio of today is 1.70.

The historical rank and industry rank for Protagenic Therapeutics's PB Ratio or its related term are showing as below:

PTIX' s PB Ratio Range Over the Past 10 Years
Min: 0.58   Med: 3.61   Max: 5.31
Current: 1.7

During the past 13 years, Protagenic Therapeutics's highest PB Ratio was 5.31. The lowest was 0.58. And the median was 3.61.

PTIX's PB Ratio is ranked better than
63.99% of 1308 companies
in the Biotechnology industry
Industry Median: 2.435 vs PTIX: 1.70

During the past 12 months, Protagenic Therapeutics's average Book Value Per Share Growth Rate was -48.30% per year.

During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of Protagenic Therapeutics was 89.80% per year. The lowest was 89.80% per year. And the median was 89.80% per year.

Back to Basics: PB Ratio


Protagenic Therapeutics PB Ratio Historical Data

The historical data trend for Protagenic Therapeutics's PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Protagenic Therapeutics PB Ratio Chart

Protagenic Therapeutics Annual Data
Trend Jun14 Jun15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - 2.40 1.00 1.20

Protagenic Therapeutics Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.00 1.17 1.62 1.92 1.20

Competitive Comparison of Protagenic Therapeutics's PB Ratio

For the Biotechnology subindustry, Protagenic Therapeutics's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Protagenic Therapeutics's PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Protagenic Therapeutics's PB Ratio distribution charts can be found below:

* The bar in red indicates where Protagenic Therapeutics's PB Ratio falls into.



Protagenic Therapeutics PB Ratio Calculation

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.

Protagenic Therapeutics's PB Ratio for today is calculated as follows:

PB Ratio=Share Price/Book Value per Share (Q: Dec. 2023)
=1.41/0.827
=1.70

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.


Protagenic Therapeutics  (NAS:PTIX) PB Ratio Explanation

Unlike valuation ratios relative to the earning power such as PE Ratio, PE Ratio without NRI, PS Ratio, Price-to-Operating-Cash-Flow , or Price-to-Free-Cash-Flow, the PB Ratio measures the valuation of the stock relative to the underlying asset of the company.

The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.


Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.


Protagenic Therapeutics PB Ratio Related Terms

Thank you for viewing the detailed overview of Protagenic Therapeutics's PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Protagenic Therapeutics (Protagenic Therapeutics) Business Description

Traded in Other Exchanges
Address
149 Fifth Avenue, Suite 500, New York, NY, USA, 10010
Protagenic Therapeutics Inc is a biopharmaceutical company focused on the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. It provides treatments for mood, anxiety, depression and neurodegenerative disorders by using peptide-based and brain active therapeutics. The company's lead compound, PT00114, is a synthetic form of Teneurin Carboxy-terminal Associated Peptide, an endogenous brain signaling peptide that can dampen overactive stress responses. It has also created a portfolio of novel neuropeptides that are in various stages of development and preclinical evaluation for the treatment of mood disorders.
Executives
Alexander K. Arrow officer: Chief Financial Officer PO BOX 3094, REDWOOD CITY CA 94064
Jennifer Buell director 3 FORBES ROAD, LEXINGTON MA 02421
Brian Corvese director C/O ANTIGENICS INC., 162 FIFTH AVENUE, SUITE 900, NEW YORK NY 10010
Robert Benjamin Stein director C/O AGENUS INC., 3 FORBES ROAD, LEXINGTON MA 02421
Khalil Barrage director 149 FIFTH AVENUE, SUITE 500, NEW YORK NY 10010
Gregory Ekizian director 149 FIFTH AVENUE, SUITE 500, NEW YORK NY 10010
Robert Ziroyan officer: COO / Interim President 149 FIFTH AVENUE, SUITE 500, NEW YORK NY 10010
Joshua Silverman director IROQUOIS CAPITAL MANAGEMENT LLC, 205 EAST 42ND ST - 20TH FL., NEW YORK NY 10017
Garo H Armen director, 10 percent owner, officer: See Remarks 3 FORBES ROAD, LEXINGTON MA 02421
Edward J Gildea director, officer: Chief Executive Officer C/O CONVERTED ORGANICS INC., 7A COMMERCIAL WHARF WEST, BOSTON MA 02110
David J Horin officer: Chief Financial Officer 1270 AVENUE OF THE AMERICAS, 16TH FLOOR, NEW YORK NY 10020
Jonathan Schechter director C/O ATRINSIC, INC. 1 GRAND CENTRAL PLACE, SUITE 2319, NEW YORK NY 10165
Nathan Yu-gai Fong officer: Chief Financial Officer THE ORCHARD ENTERPRISES, INC., 23 E. 4TH ST., 3RD FL., NEW YORK NY 10003
Sharon Siegel officer: Chief Marketing Officer C/O ATRINSIC, INC., 469 SEVENTH AVENUE, 10TH FLOOR, NEW YORK NY 10018
Raymond Musci director, officer: Exec VP, Corporate Development C/O BRILLIANT DIGITAL ENTERTAINMENT INC, 6355 TOPANGA CANYON BOULEVARD SUITE 520, WOODLAND HILLS CA 91367

Protagenic Therapeutics (Protagenic Therapeutics) Headlines

From GuruFocus

Protagenic Therapeutics to Effect 1-for-4 Reverse Stock Split

By ACCESSWIRE ACCESSWIRE 03-22-2023